The recent weakness has been attributed by some to the Summer doldrums, they seem to happen in biotechs this time of year. I'm taking advantage of it by purchasing cheap January calls and in that I believe $20 is possible by then, I'm buying the $14's.
News 
Market Data 
Discover 
